<?xml-stylesheet type="text/xsl" href="ViewNLM-v2.3.xsl"?><!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Korean Med Sci</journal-id><journal-id journal-id-type="publisher-id">JKMS</journal-id><journal-title-group><journal-title>Journal of Korean Medical Science</journal-title></journal-title-group><issn pub-type="ppub">1011-8934</issn><issn pub-type="epub">1598-6357</issn><publisher><publisher-name>The Korean Academy of Medical Sciences</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.3346/jkms.2006.21.4.645</article-id><article-id pub-id-type="pmid">16891807</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>nm23-H1 Protein Expression and Gene Mutation in 150 Patients with Non-Hodgkin's Lymphomas</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Ju-Han</given-names></name><xref ref-type="aff" rid="A1"/></contrib><contrib contrib-type="author"><name><surname>Cho</surname><given-names>Su Jin</given-names></name><xref ref-type="aff" rid="A1"/></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Xianglan</given-names></name><xref ref-type="aff" rid="A1"/></contrib><contrib contrib-type="author"><name><surname>Zheng</surname><given-names>Zhenlong</given-names></name><xref ref-type="aff" rid="A1"/></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Eung Seok</given-names></name><xref ref-type="aff" rid="A1"/></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Aeree</given-names></name><xref ref-type="aff" rid="A1"/></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Young-Sik</given-names></name><xref ref-type="aff" rid="A1"/></contrib><contrib contrib-type="author"><name><surname>Chae</surname><given-names>Yang-seok</given-names></name><xref ref-type="aff" rid="A1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Kim</surname><given-names>Insun</given-names></name><xref ref-type="aff" rid="A1"/></contrib></contrib-group><aff id="A1">Department of Pathology, College of Medicine, Korea University, Seoul, Korea.</aff><author-notes><corresp>Address for correspondence: Insun Kim, M.D. Department of Pathology, Korea Univerdity School of Medicine, Guro Hospital, 80 Guro-dong, Guro-gu, Seoul 152-703, Korea. Tel: +82.2-818-6871, Fax: +82.2-818-6239, <email>iskim@korea.ac.kr</email></corresp></author-notes><pub-date pub-type="ppub"><month>8</month><year>2006</year></pub-date><pub-date pub-type="epub"><day>22</day><month>8</month><year>2006</year></pub-date><volume>21</volume><issue>4</issue><fpage>645</fpage><lpage>651</lpage><history><date date-type="received"><day>24</day><month>11</month><year>2005</year></date><date date-type="accepted"><day>02</day><month>1</month><year>2006</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2006 The Korean Academy of Medical Sciences</copyright-statement><copyright-year>2006</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0">http://creativecommons.org/licenses/by-nc/3.0</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>The metastasis-suppressing role of the <italic>nm23</italic> gene in the metastatic spread of malignant tumor is still debated. We examined the nm23-H1 protein expression and gene mutation in non-Hodgkin's lymphomas to compare with the clinicopathologic parameters. The expression of nm23-H1 protein was immunohistochemically examined in 150 cases of non-Hodgkin's lymphomas; 85 diffuse large B cell lymphomas (DLBCL), 18 marginal zone B cell lymphomas (MZL), 3 mantle cell lymphomas, 25 peripheral T cell lymphomas, not otherwise specified (TCLNOS), and 19 NK/T cell lymphomas (NK/T). Eighty-one cases (58 DLBCL, 6 MZL, 4 TCLNOS, and 13 NK/T) were studied for <italic>nm23-H1</italic> gene mutation in exon 1 to 5. The high expression of nm23-H1 protein was associated with the high IPI score (<italic>p</italic>=0.019) and the low survival rate of the patients (<italic>p</italic>=0.0039). The gene mutation of <italic>nm23-H1</italic> was detected in 10.3% of DLBCL and 30.7% of NK/T; but none in MZL and TCLNOS. The mutation was found in exon 1 in 5 cases, exon 2 in two cases, exon 4 in one case and both exon 1 and 2 in two cases. Our results suggest that the expression of nm23-H1 protein can be used as a poor prognostic marker in non-Hodgkin's lymphomas, and the mutational change of gene may operate in the lymphomagenesis.</p></abstract><kwd-group><kwd>nucleoside diphosphate kinase A</kwd><kwd>nm23-H1 Protein</kwd><kwd>Lymphoma, Non-Hodgkin</kwd><kwd>Mutation</kwd><kwd>Prognosis</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p>The <italic>nm23</italic> gene was first classified as a metastasis suppressor gene on the basis of its reduced expression in several metastatic melanoma cell lines relative to nonmetastatic counterparts (<xref ref-type="bibr" rid="B1">1</xref>). Subsequently, the low expression of nm23-H1 protein has been described as being linked to an increased metastatic potential in breast carcinoma, hepatoma, and gastric carcinoma, implying its role at inhibiting metastasis in a variety of human cancers (<xref ref-type="bibr" rid="B2">2</xref>-<xref ref-type="bibr" rid="B4">4</xref>). In other tumors, such as neuroblastoma, pancreatic carcinoma, and head and neck carcinomas, surprisingly, the opposite trend has been reported (<xref ref-type="bibr" rid="B5">5</xref>-<xref ref-type="bibr" rid="B7">7</xref>).</p><p>Malignant lymphomas constitute a heterogenous group of disorders, comprising different histogenesis and variable clinical outcomes. The histologic types and clinical staging are well known as prognostic indicators. Nevertheless they cannot accurately predict a clinical outcome in an individual case. Thus, a continuous necessity for reproducible quantitative methods has been required to confer additional prognostic information and to guide the clinician in the selection of the most appropriate therapeutic approach.</p><p>The previous studies of nm23-H1 expression in malignant lymphomas revealed that overall survival rates were significantly lower in the patients with nm23-H1-positive lymphomas than in those with nm23-H1-negative lymphomas (<xref ref-type="bibr" rid="B8">8</xref>-<xref ref-type="bibr" rid="B12">12</xref>). There has been only one study describing no mutational change of <italic>nm23-H1</italic> gene in malignant lymphomas (<xref ref-type="bibr" rid="B13">13</xref>). The aims of this study are to determine the significance of nm23-H1 protein expression as a prognostic indicator and to detect the frequency of <italic>nm23-H1</italic> gene mutation in non-Hodgkin's lymphomas.</p></sec><sec sec-type="methods"><title>MATERIALS AND METHODS</title><sec><title>Materials</title><p>One hundred fifty non-Hodgkin's lymphomas were selected from the pathology file in the Department of Pathology, Anam and Guro Hospitals of Korea University, Korea. The tissues were routinely processed with 10% buffered formalin fixation and paraffin embedding. The diagnosis and classification of lymphomas were dependent upon the routine histologic sections and immunohistochemical staining. They were supplemented by TCR&#x003b3; rearrangement study and followed by the WHO classification (<xref ref-type="bibr" rid="B14">14</xref>). The studied cases were 106 B cell lymphomas (85 diffuse large B cell lymphomas [DLBCL], 18 marginal zone B cell lymphomas [MZL], and 3 mantle cell lymphomas [MCL]), and 44 T cell lymphomas (25 peripheral T cell lymphoma, not otherwise specified [TCLNOS], and 19 NK/T cell lymphomas [NK/T]). Forty-two cases were nodal and 108 cases were extranodal. The extranodal sites were 44 gastrointestinal tracts, 17 nasal cavities, 15 Waldeyer's rings, 12 ocular adnexae, 3 salivary glands, 3 thyroid glands, 3 testes, and 11 others. The median age of patients was 53.8 yr (15-88 yr). Ninty-six patients were male and fifty-four patients female. The patients were classified according to the Ann Arbor clinical staging system; 49 stage I, 58 stage II, 28 stage III, and 15 stage IV. The patients were classified according to the International Prognostic Index (IPI); 105 low risk (0, 1), 33 intermediate risk (2, 3), and 12 high risk (4, 5). Twenty-seven patients died from malignant lymphoma between 1 month to 58 months (mean; 13.7 months). One hundred twenty-three patients survived, and the mean follow-up duration was 26.9 months (2-120). This investigation was performed after obtaining an informed consent from all the patients involved in our study.</p></sec><sec><title>Tissue microarray</title><p>All slides were reviewed, and the appropriate area was marked and selected for tissue microarray. Agar blocks for tissue microarray were prepared as follows; Agar (4 g) was dissolved into 100 mL distilled water and boiled in microwave for 2 min. It was solidified in the cast and routinely processed as a tissue sample. The agar was embedded in paraffin. The selected area of each case was holed by the punch biopsy tool (2 mm in diameter) and transplanted into the agar block, holed by the same biopsy tool. After all of the cases were reembedded into the agar block, the block was incubated at 37&#x02103; for 30 min to mould the tissue in paraffin.</p></sec><sec><title>Immunohistochemical staining</title><p>The expression of nm23-H1 protein was immunohistochemically stained on 4 &#x000b5;m thick section from microarray blocks by the use of LSAB method. Monoclonal antibody to nm23-H1 (1:100, Novocastra Laboratories Ltd, U.K.) was used as a primary antibody. Immunohistochemical staining results for nm23-H1 protein were classified according to the following criteria: (-), when less than 5% of tumor cells were positive; (1+), when 5-50% of tumor cells were positive; (2+), when more than 50% of the tumor cells were positive (<xref ref-type="fig" rid="F1">Fig. 1</xref>).</p></sec><sec><title>PCR-SSCP analysis and DNA sequencing</title><p>Total 81 cases (58 DLBCL, 6 MZL, 4 TCLNOS, 13 NK/T) were available for mutation study. DNA was extracted from the formalin-fixed, paraffin-embedded tissue sections by the use of the standard method with proteinase K digestion and phenol/chloroform purification. The primers for PCR were designed to amplify exons 1-5 as follows; Exon 1: (forward) 5'gtctgaaaaacgtagcgccgg3', (reverse) 5'cttaggtttgaactccggctg 3', Exon 2: (forward) 5'gcttgagacggatgacgctgta3', (reverse) 5'caggttaatcacagtgttctcc3', Exon 3: (forward) 5'atgtccttagatggtttgggggt3', (reverse) 5'tttggtctcattcatggctgtat3', Exon 4: (forward) 5'gccacattttctgctgtgatt3', (reverse) 5'cccaaatccttgtggcaact3', Exon 5; (forward) 5'gtctaatgtccatggagcttc3', (reverse) 5'cagatggtcggggatggtaac3'. The total 20 &#x000b5;L reaction volume contained 3 &#x000b5;L template, 1 &#x000b5;L out of each oligonucleotide primer, 2 &#x000b5;L dNTP, 11 &#x000b5;L ddH<sub>2</sub>O, 0.2 &#x000b5;L <italic>Taq</italic> polymerase, and 2 &#x000b5;L 10 &#x000d7; PCR buffer with Mg<sup>2+</sup>. Cycling conditions were as follows; an initial penetration at 95&#x02103; for 5 min, 40 cycles each at 94&#x02103; for 1 min, at 56&#x02103; for 30 sec, at 72&#x02103; for 30 sec, followed by one cycle at 72&#x02103; for 10 min. PCR products were visualized by electrophoresis in 1.8% (w/v) agarose gel. Then the products were subjected to 8% non-denaturation polyacrylamide gel electrophoresis and stained with silver nitrate. DNA sequencing was performed in the cases showing abnormal bands on PCR-SSCP by the use of the Automatic Sequencer ABI 3730 (Applied Biosystem, Foster city, CA, U.S.A.).</p></sec><sec><title>Statistical analysis</title><p>Statistical significance was evaluated by using Kruskal-Wallis test for independent groups. The survival curves were calculated by using the Kaplan-Meier method, and then compared with other prognostic variables by using a log-rank test. All statistical analyses were two-sided with a significance level of <italic>p</italic>&#x02264;0.05, and all analyses were performed by using the SPSS statistical software (version 10.0, SPSS Inc., Chicago, IL, U.S.A.).</p></sec></sec><sec sec-type="results"><title>RESULTS</title><p>The immunostaining for nm23-H1 protein in a reactive lymph node showed a positive reaction in the cytoplasm of centroblasts in germinal centers and transformed lymphocytes in the interfollicular area. The staining in lymphoma cells was also primarily cytoplasmic. Of the 150 non-Hodgkin's lymphomas, 58 (38.6%) cases were (2+) and 46 (30.7%) cases (1+) for nm23-H1 protein (<xref ref-type="table" rid="T1">Table 1</xref>). According to the histologic types, 45.9% of DLBCL, 16.7% of MZL, 66.7% of MCL, 28.0% of TCLNOS, and 36.8% of NK/T lymphomas were (2+). In MZL, there was a lower expression tendency of nm23-H1 protein than in other types without statistical significance. The age, sex, and the nodal or extranodal sites were not correlated with nm23-H1 protein expression (<xref ref-type="table" rid="T2">Table 2</xref>). The nm23-H1 protein expression was significantly correlated with IPI score (<italic>p</italic>=0.019) but not with the Ann Arbor clinical stage (<xref ref-type="table" rid="T3">Table 3</xref>).</p><p>The survival rates in T cell lymphomas were worse than in B cell lymphoma (<italic>p</italic>=0.0415, <xref ref-type="table" rid="T4">Table 4</xref>). The higher Ann Arbor clinical stages (<italic>p</italic>=0.0000, <xref ref-type="table" rid="T4">Table 4</xref>), and IPI scores (<italic>p</italic>=0.0000, <xref ref-type="table" rid="T4">Table 4</xref>) were significantly associated with poor outcomes. The patients with (2+) expression of nm23-H1 protein showed the lower survival rate than those with negative or (1+) expression (<italic>p</italic>=0.0039, <xref ref-type="table" rid="T4">Table 4</xref>, <xref ref-type="fig" rid="F2">Fig. 2</xref>). The high expression of nm23-H1 protein was associated with poor survival rates in B and T cell lymphomas (<italic>p</italic>=0.0013, <xref ref-type="fig" rid="F3">Fig. 3</xref>). Even in the same Ann Arbor clinical stages (stage I, II and stage III, IV), and IPI groups (low, intermediate, and high), the patients with (2+) expression of nm23-H1 protein showed the lower survival rate than those with negative or (1+) expression (<italic>p</italic>=0.0042 and <italic>p</italic>=0.0483, <xref ref-type="fig" rid="F4">Fig. 4</xref>).</p><p>By PCR-SSCP technique, the mutations were detected in 6 cases (10.3%) out of DLBCL and 4 cases (30.7%) out of NK/T. No mutation was found in MZL and TCLNOS (<xref ref-type="table" rid="T5">Table 5</xref>). These mutations were not correlated with age (<italic>p</italic>=0.071), sex (<italic>p</italic>=0.813), nodal or extranodal sites (<italic>p</italic>=0.738), Ann Arbor clinical stage (<italic>p</italic>=0.412), IPI (<italic>p</italic>=0.239), and survival rate (<italic>p</italic>= 0.1208). The mutation sites were as follows; five cases in exon 1, two cases in exon 2, two cases in exon 1 and 2, and one case in exon 4. Sequencing was performed in eight out of ten cases. All of the four cases with exon 1 mutation showed C&#x02192;G transversion at nucleotide 55 (gi 468541) (<xref ref-type="fig" rid="F5">Fig. 5</xref>). Three out of four cases with mutation in exon 2 showed insertional mutation after the nucleotide at 2257 (gi 468541) and the other one showed insertional mutation after the nucleotide at 2084 (<xref ref-type="fig" rid="F5">Fig. 5</xref>). There was a weak correlation between the mutations and protein expression of nm23-H1 (<italic>p</italic>=0.057).</p></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>The human protein nm23-H1 is one of the human homologues of <italic>Drosophila</italic> awd (<xref ref-type="bibr" rid="B15">15</xref>). Eight different genes of this family have been identified in human, and their expressions are linked to suppression of tumor metastasis, differentiation, apoptosis, and proliferation (<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B17">17</xref>). <italic>nm23-H1</italic> and -H2 are nucleoside diphophate kinase, and metastasis suppression was observed in several tumor cell lines transfected with <italic>nm23-H1</italic> gene (<xref ref-type="bibr" rid="B18">18</xref>,<xref ref-type="bibr" rid="B19">19</xref>). However, the biochemical mechanisms underlying the metastasis-suppressing action of nm23-H1 are largely unknown. The nm23 proteins are multifunctional, and they interact with many different proteins, some of which are involved in cancer progression (<xref ref-type="bibr" rid="B20">20</xref>). Indeed, the amount of nm23 increased in normal lymphocytes in response to mitotic stimulation and paralleled the increase in DNA synthesis (<xref ref-type="bibr" rid="B21">21</xref>). Our results also demonstrate the high expression of nm23-H1 protein is associated with poor prognosis. Therefore, the nm23 protein has a different and possibly varied role in tumors of different origins.</p><p>Niitsu et al. (<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B12">12</xref>) reported that serum levels of nm23-H1 in aggressive non-Hodgkin's lymphomas were significantly higher than those in controls, and that high nm23-H1 levels were correlated with poor prognosis. Moreover, Niitsu et al. (<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B9">9</xref>) reported 58.1% (100/172 patients) of DLBCL, 33.3% (5/15 patients) of MZL, 66.7% (12/18 patients) of MCL, 25.5% (12/47 patients) of TCLNOS, and 42.9% (9/21 patients) of NK/T were strongly positive (more than 70%) for nm23-H1. The survival rates were significantly lower in the patients with nm23-H1-positive lymphomas than in those with nm23-H1-negative lymphomas.</p><p>In our study, the degree of nm23-H1 protein expression was significantly correlated with IPI, but not with the age, sex, nodal or extranodal sites, and histologic types. The strong expression of nm23-H1 protein was significantly correlated with poor survival rate. Even in the same Ann Arbor clinical stage, IPI and histologic type (B and T cell lymphomas), the high expression of nm23-H1 protein was significantly correlated with poor survival rates. The results of this study were similar to the previous reports of Niistu et al. (<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B9">9</xref>).</p><p>Mutational events of <italic>nm23</italic> have not been frequently observed in human cancers, and its role in malignancy is controversial (<xref ref-type="bibr" rid="B22">22</xref>). Some data on colon and ovarian cancers suggested that mutations of <italic>nm23-H1</italic> gene were associated with the presence of metastases, advanced disease, and poor survival (<xref ref-type="bibr" rid="B23">23</xref>,<xref ref-type="bibr" rid="B24">24</xref>). In neuroblastoma, a particular point mutation (Ser 120 Gly) affecting the protein folding was related to the aggressiveness (<xref ref-type="bibr" rid="B25">25</xref>). However, other groups were unable to detect any mutation of <italic>nm23-H1</italic> gene in liver metastases of colon cancer, breast cancer, and hepatocellular carcinoma (<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B26">26</xref>-<xref ref-type="bibr" rid="B28">28</xref>). In malignant lymphomas, the mutational study by Aryee et al. (<xref ref-type="bibr" rid="B13">13</xref>) did not show any mutations by PCR-SSCP method.</p><p>In this study, we evaluated the <italic>nm23-H1</italic> gene mutation by PCR-SSCP method and sequencing. We detected <italic>nm23-H1</italic> mutation in non-Hodgkin's lymphoma. Ten out of eighty-one cases showed <italic>nm23-H1</italic> mutations by PCR-SSCP method. These mutations were not correlated with clinicopathologic parameters. However, interestingly enough, the mutation was only found in DLBCL and NK/T lymphomas, but not in other types. In addition, the point mutation of exon 1 and insertional mutation of exon 2 were detected at the same sites; C to G transversion at nucleotide 55 of exon 1, and insertional mutation after the nucleotide at 2257. Bafico et al. (<xref ref-type="bibr" rid="B29">29</xref>) reported that a common polymorphic sequence (C to T transition, 30 nucleotides upstream from the 5'splice site of exon 1) in colorectal cancers, and Cipollini et al. (<xref ref-type="bibr" rid="B22">22</xref>) found that <italic>nm23-H1</italic> gene mutation (C to A transversion at nucleotide -79 of exon 1) in breast cancers. The same sequence variants as the present study have not been described so far.</p><p>Because nm23-H1 protein can be easily examined at the time of conventional phenotypic examinations for the diagnosis of lymphoma, it may be used as a prognostic marker of non-Hodgkin's lymphoma in addition to known prognostic indicators. We found the new mutation sites in <italic>nm23-H1</italic> gene. The role of these mutations in non-Hodgkin's lymphoma needs further investigation.</p></sec></body><back><fn-group><fn fn-type="supported-by"><p>This study is supported by <funding-source>Brain Korea 21 Project</funding-source>.</p></fn></fn-group><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steeg</surname><given-names>PS</given-names></name><name><surname>Bevilacqua</surname><given-names>G</given-names></name><name><surname>Kopper</surname><given-names>L</given-names></name><name><surname>Thorgeirsson</surname><given-names>UP</given-names></name><name><surname>Talmadge</surname><given-names>JE</given-names></name><name><surname>Liotta</surname><given-names>LA</given-names></name><name><surname>Sobel</surname><given-names>ME</given-names></name></person-group><article-title>Evidence for a novel gene associated with low tumor metastatic potential</article-title><source>J Natl Cancer Inst</source><year>1988</year><volume>80</volume><fpage>200</fpage><lpage>204</lpage><pub-id pub-id-type="pmid">3346912</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mao</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Fu</surname><given-names>X</given-names></name><name><surname>Fang</surname><given-names>Z</given-names></name><name><surname>Abrams</surname><given-names>J</given-names></name><name><surname>Worsham</surname><given-names>MJ</given-names></name></person-group><article-title>Loss of nm23 expression predicts distal metastases and poorer survival for breast cancer</article-title><source>Int J Oncol</source><year>2001</year><volume>18</volume><fpage>587</fpage><lpage>591</lpage><pub-id pub-id-type="pmid">11179491</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujimoto</surname><given-names>Y</given-names></name><name><surname>Ohtake</surname><given-names>T</given-names></name><name><surname>Nishimori</surname><given-names>H</given-names></name><name><surname>Ikuta</surname><given-names>K</given-names></name><name><surname>Ohhira</surname><given-names>M</given-names></name><name><surname>Ono</surname><given-names>M</given-names></name><name><surname>Kohgo</surname><given-names>Y</given-names></name></person-group><article-title>Reduced expression and rare genomic alteration of nm23-H1 in human hepatocellular carcinoma and hepatoma cell lines</article-title><source>J Gastroenterol</source><year>1998</year><volume>33</volume><fpage>368</fpage><lpage>375</lpage><pub-id pub-id-type="pmid">9658316</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>YJ</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>HR</given-names></name><name><surname>Kim</surname><given-names>DY</given-names></name><name><surname>Kim</surname><given-names>SK</given-names></name><name><surname>Kim</surname><given-names>KK</given-names></name><name><surname>Park</surname><given-names>S</given-names></name></person-group><article-title>Expression of the nm23 gene in primary and metastatic gastric cancer tissues</article-title><source>J Korean Surg Soc</source><year>1999</year><volume>57</volume><fpage>836</fpage><lpage>842</lpage></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leone</surname><given-names>A</given-names></name><name><surname>Seeger</surname><given-names>RC</given-names></name><name><surname>Hong</surname><given-names>CM</given-names></name><name><surname>Hu</surname><given-names>YY</given-names></name><name><surname>Arboleda</surname><given-names>MJ</given-names></name><name><surname>Brodeur</surname><given-names>GM</given-names></name><name><surname>Stram</surname><given-names>D</given-names></name><name><surname>Slamon</surname><given-names>DJ</given-names></name><name><surname>Steeg</surname><given-names>PS</given-names></name></person-group><article-title>Evidence for nm23 RNA overexpression, DNA amplification and mutation in aggressive childhood neuroblastomas</article-title><source>Oncogene</source><year>1993</year><volume>8</volume><fpage>855</fpage><lpage>865</lpage><pub-id pub-id-type="pmid">8384356</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakamori</surname><given-names>S</given-names></name><name><surname>Ishikawa</surname><given-names>O</given-names></name><name><surname>Ohigashi</surname><given-names>H</given-names></name><name><surname>Imaoka</surname><given-names>S</given-names></name><name><surname>Sasaki</surname><given-names>Y</given-names></name><name><surname>Kameyama</surname><given-names>M</given-names></name><name><surname>Kabuto</surname><given-names>T</given-names></name><name><surname>Furukawa</surname><given-names>H</given-names></name><name><surname>Iwanakga</surname><given-names>T</given-names></name><name><surname>Kimura</surname><given-names>N</given-names></name></person-group><article-title>Clinicopathological features and prognostic significance of nucleoside diphosphate kinase/nm23 gene product in human pancreatic exocrine neoplasms</article-title><source>Int J Pancreatol</source><year>1993</year><volume>14</volume><fpage>125</fpage><lpage>133</lpage><pub-id pub-id-type="pmid">8283076</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pavelic</surname><given-names>K</given-names></name><name><surname>Kapitanovic</surname><given-names>S</given-names></name><name><surname>Radosevic</surname><given-names>S</given-names></name><name><surname>Bura</surname><given-names>M</given-names></name><name><surname>Seiwerth</surname><given-names>S</given-names></name><name><surname>Pavelic</surname><given-names>LJ</given-names></name><name><surname>Unusic</surname><given-names>J</given-names></name><name><surname>Spaventi</surname><given-names>R</given-names></name></person-group><article-title>Increased activity of nm23-H1 gene in squamous cell carcinoma of the head and neck is associated with advanced disease and poor prognosis</article-title><source>Mol Med</source><year>2000</year><volume>78</volume><fpage>111</fpage><lpage>118</lpage></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niitsu</surname><given-names>N</given-names></name><name><surname>Nakamine</surname><given-names>H</given-names></name><name><surname>Okamoto</surname><given-names>M</given-names></name><name><surname>Akamatsu</surname><given-names>H</given-names></name><name><surname>Higashihara</surname><given-names>M</given-names></name><name><surname>Honma</surname><given-names>Y</given-names></name><name><surname>Okabe-Kado</surname><given-names>J</given-names></name><name><surname>Hirano</surname><given-names>M</given-names></name></person-group><article-title>Clinical significance of intracytoplasmic nm23-H1 expression in diffuse large B-cell lymphoma</article-title><source>Clin Cancer Res</source><year>2004</year><volume>10</volume><fpage>2482</fpage><lpage>2490</lpage><pub-id pub-id-type="pmid">15073128</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niitsu</surname><given-names>N</given-names></name><name><surname>Nakamine</surname><given-names>H</given-names></name><name><surname>Okamoto</surname><given-names>M</given-names></name><name><surname>Akamatsu</surname><given-names>H</given-names></name><name><surname>Honma</surname><given-names>Y</given-names></name><name><surname>Higashihara</surname><given-names>M</given-names></name><name><surname>Okabe-Kado</surname><given-names>J</given-names></name><name><surname>Hirano</surname><given-names>M</given-names></name></person-group><collab>Adult Lymphoma Treatment Study Group, ALTSG</collab><article-title>Expression of nm23-H1 is associated with poor prognosis in peripheral T-cell lymphoma</article-title><source>Br J Haematol</source><year>2003</year><volume>123</volume><fpage>621</fpage><lpage>630</lpage><pub-id pub-id-type="pmid">14616965</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niitsu</surname><given-names>N</given-names></name><name><surname>Honma</surname><given-names>Y</given-names></name><name><surname>Iijima</surname><given-names>K</given-names></name><name><surname>Takagi</surname><given-names>T</given-names></name><name><surname>Higashihara</surname><given-names>M</given-names></name><name><surname>Sawada</surname><given-names>U</given-names></name><name><surname>Okabe-Kado</surname><given-names>J</given-names></name></person-group><article-title>Clinical significance of nm23-H1 proteins expressed on cell surface in non-Hodgkin's lymphoma</article-title><source>Leukemia</source><year>2003</year><volume>17</volume><fpage>196</fpage><lpage>202</lpage><pub-id pub-id-type="pmid">12529678</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niitsu</surname><given-names>N</given-names></name><name><surname>Okabe-Kado</surname><given-names>J</given-names></name><name><surname>Kasukabe</surname><given-names>T</given-names></name><name><surname>Yamamoto-Yamaguchi</surname><given-names>Y</given-names></name><name><surname>Umeda</surname><given-names>M</given-names></name><name><surname>Homma</surname><given-names>Y</given-names></name></person-group><article-title>Prognostic implications of the differentiation inhibitory factor nm23-H1 protein in the plasma of aggressive non-Hodgkin's lymphoma</article-title><source>Blood</source><year>1999</year><volume>94</volume><fpage>3541</fpage><lpage>3550</lpage><pub-id pub-id-type="pmid">10552965</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niitsu</surname><given-names>N</given-names></name><name><surname>Okabe-Kado</surname><given-names>J</given-names></name><name><surname>Okamoto</surname><given-names>M</given-names></name><name><surname>Takagi</surname><given-names>T</given-names></name><name><surname>Yoshida</surname><given-names>T</given-names></name><name><surname>Aoki</surname><given-names>S</given-names></name><name><surname>Hirano</surname><given-names>M</given-names></name><name><surname>Honma</surname><given-names>Y</given-names></name></person-group><article-title>Serum nm23-H1 protein as a prognostic factor in aggressive non-Hodgkin lymphoma</article-title><source>Blood</source><year>2001</year><volume>97</volume><fpage>1202</fpage><lpage>1210</lpage><pub-id pub-id-type="pmid">11222361</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aryee</surname><given-names>DN</given-names></name><name><surname>Simonitsch</surname><given-names>I</given-names></name><name><surname>Mosberger</surname><given-names>I</given-names></name><name><surname>Kos</surname><given-names>K</given-names></name><name><surname>Mann</surname><given-names>G</given-names></name><name><surname>Schlogl</surname><given-names>E</given-names></name><name><surname>Potschger</surname><given-names>U</given-names></name><name><surname>Gadner</surname><given-names>H</given-names></name><name><surname>Radaszkiewicz</surname><given-names>T</given-names></name><name><surname>Kovar</surname><given-names>H</given-names></name></person-group><article-title>Variability of nm23-H1/NDPK-A expression in human lymphomas and its relation to tumour aggressiveness</article-title><source>Br J Cancer</source><year>1996</year><volume>74</volume><fpage>1693</fpage><lpage>1698</lpage><pub-id pub-id-type="pmid">8956779</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="book"><person-group person-group-type="editor"><name><surname>Jaffe</surname><given-names>ES</given-names></name><name><surname>Haris</surname><given-names>NL</given-names></name><name><surname>Stein</surname><given-names>H</given-names></name><name><surname>Vardiman</surname><given-names>JW</given-names></name></person-group><source>Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues (World Health Organization Classification of Tumours)</source><year>2001</year><publisher-loc>Lyon</publisher-loc><publisher-name>IARC Press</publisher-name></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biggs</surname><given-names>J</given-names></name><name><surname>Hersperger</surname><given-names>E</given-names></name><name><surname>Steeg</surname><given-names>PS</given-names></name><name><surname>Liotta</surname><given-names>LA</given-names></name><name><surname>Shearn</surname><given-names>A</given-names></name></person-group><article-title>A Drosophila gene that is homologous to a mammalian gene associated with tumor metastasis codes for a nucleoside diphosphate kinase</article-title><source>Cell</source><year>1990</year><volume>63</volume><fpage>933</fpage><lpage>940</lpage><pub-id pub-id-type="pmid">2175255</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lombardi</surname><given-names>D</given-names></name><name><surname>Lacombe</surname><given-names>ML</given-names></name><name><surname>Paggi</surname><given-names>MG</given-names></name></person-group><article-title>nm23: unrevealing its biological function in cell differentiation</article-title><source>J Cell Physiol</source><year>2000</year><volume>182</volume><fpage>144</fpage><lpage>149</lpage><pub-id pub-id-type="pmid">10623877</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de la Rosa</surname><given-names>A</given-names></name><name><surname>Williams</surname><given-names>RL</given-names></name><name><surname>Steeg</surname><given-names>PS</given-names></name></person-group><article-title>Nm23/nucleoside diphosphate kinase: toward a structural and biochemical understanding of its biological functions</article-title><source>Bioessays</source><year>1995</year><volume>17</volume><fpage>53</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">7702594</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leone</surname><given-names>A</given-names></name><name><surname>Flatow</surname><given-names>U</given-names></name><name><surname>King</surname><given-names>CR</given-names></name><name><surname>Sandeen</surname><given-names>MA</given-names></name><name><surname>Margulies</surname><given-names>IM</given-names></name><name><surname>Liotta</surname><given-names>LA</given-names></name><name><surname>Steeg</surname><given-names>PS</given-names></name></person-group><article-title>Reduced tumor incidence, metastatic potential, and cytokine responsiveness of nm23-transfected melanoma cells</article-title><source>Cell</source><year>1991</year><volume>65</volume><fpage>25</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">2013093</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russell</surname><given-names>RL</given-names></name><name><surname>Pedersen</surname><given-names>AN</given-names></name><name><surname>Kantor</surname><given-names>J</given-names></name><name><surname>Geisinger</surname><given-names>K</given-names></name><name><surname>Long</surname><given-names>R</given-names></name><name><surname>Zbieranski</surname><given-names>N</given-names></name><name><surname>Townsend</surname><given-names>A</given-names></name><name><surname>Shelton</surname><given-names>B</given-names></name><name><surname>Brunner</surname><given-names>N</given-names></name><name><surname>Kute</surname><given-names>TE</given-names></name></person-group><article-title>Relationship of nm23 to proteolytic factors, proliferation and motility in breast cancer tissues and cell lines</article-title><source>Br J Cancer</source><year>1998</year><volume>78</volume><fpage>710</fpage><lpage>717</lpage><pub-id pub-id-type="pmid">9743288</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lombardi</surname><given-names>D</given-names></name><name><surname>Mileo</surname><given-names>AM</given-names></name></person-group><article-title>Protein interactions provide new insight into Nm23/nucleoside diphosphate kinase functions</article-title><source>J Bioenerg Biomembr</source><year>2003</year><volume>35</volume><fpage>67</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">12848343</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keim</surname><given-names>D</given-names></name><name><surname>Hailat</surname><given-names>N</given-names></name><name><surname>Melhem</surname><given-names>R</given-names></name><name><surname>Zhu</surname><given-names>XX</given-names></name><name><surname>Lascu</surname><given-names>I</given-names></name><name><surname>Veron</surname><given-names>M</given-names></name><name><surname>Strahler</surname><given-names>J</given-names></name><name><surname>Hanash</surname><given-names>SM</given-names></name></person-group><article-title>Proliferation-related expression of p19/nm23 nucleoside diphosphate kinase</article-title><source>J Clin Invest</source><year>1992</year><volume>89</volume><fpage>919</fpage><lpage>924</lpage><pub-id pub-id-type="pmid">1311721</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cipollini</surname><given-names>G</given-names></name><name><surname>Moretti</surname><given-names>A</given-names></name><name><surname>Ghimenti</surname><given-names>C</given-names></name><name><surname>Viacava</surname><given-names>P</given-names></name><name><surname>Bevilacqua</surname><given-names>G</given-names></name><name><surname>Caligo</surname><given-names>MA</given-names></name></person-group><article-title>Mutational analysis of the NM23.H1 gene in human breast cancer</article-title><source>Cancer Genet Cytogenet</source><year>2000</year><volume>121</volume><fpage>181</fpage><lpage>185</lpage><pub-id pub-id-type="pmid">11063804</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Patel</surname><given-names>U</given-names></name><name><surname>Ghosh</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>HC</given-names></name><name><surname>Banerjee</surname><given-names>S</given-names></name></person-group><article-title>Mutation in the nm23 gene is associated with metastasis in colorectal cancer</article-title><source>Cancer Res</source><year>1993</year><volume>53</volume><fpage>3652</fpage><pub-id pub-id-type="pmid">8339271</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mandai</surname><given-names>M</given-names></name><name><surname>Konishi</surname><given-names>I</given-names></name><name><surname>Komatsu</surname><given-names>T</given-names></name><name><surname>Mori</surname><given-names>T</given-names></name><name><surname>Arao</surname><given-names>S</given-names></name><name><surname>Nomura</surname><given-names>H</given-names></name><name><surname>Kanda</surname><given-names>Y</given-names></name><name><surname>Hiai</surname><given-names>H</given-names></name><name><surname>Fukumoto</surname><given-names>M</given-names></name></person-group><article-title>Mutation of the nm23 gene, loss of heterozygosity at the nm23 locus and K-ras mutation in ovarian carcinoma: correlation with tumour progression and nm23 gene expression</article-title><source>Br J Cancer</source><year>1995</year><volume>72</volume><fpage>691</fpage><lpage>695</lpage><pub-id pub-id-type="pmid">7669582</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lascu</surname><given-names>I</given-names></name><name><surname>Schaertl</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Sarger</surname><given-names>C</given-names></name><name><surname>Giartosio</surname><given-names>A</given-names></name><name><surname>Briand</surname><given-names>G</given-names></name><name><surname>Lacombe</surname><given-names>ML</given-names></name><name><surname>Konrad</surname><given-names>M</given-names></name></person-group><article-title>A point mutation of human nucleoside diphosphate kinase A found in aggressive neuroblastoma affects protein folding</article-title><source>J Biol Chem</source><year>1997</year><volume>272</volume><fpage>15599</fpage><lpage>15602</lpage><pub-id pub-id-type="pmid">9188446</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heide</surname><given-names>I</given-names></name><name><surname>Thiede</surname><given-names>C</given-names></name><name><surname>Poppe</surname><given-names>K</given-names></name><name><surname>de Kant</surname><given-names>E</given-names></name><name><surname>Huhn</surname><given-names>D</given-names></name><name><surname>Rochlitz</surname><given-names>C</given-names></name></person-group><article-title>Expression and mutational analysis of Nm23-H1 in liver metastases of colorectal cancer</article-title><source>Br J Cancer</source><year>1994</year><volume>70</volume><fpage>1267</fpage><lpage>1271</lpage><pub-id pub-id-type="pmid">7981087</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Callahan</surname><given-names>R</given-names></name><name><surname>Cropp</surname><given-names>C</given-names></name><name><surname>Sheng</surname><given-names>ZM</given-names></name><name><surname>Merlo</surname><given-names>G</given-names></name><name><surname>Steeg</surname><given-names>P</given-names></name><name><surname>Liscia</surname><given-names>D</given-names></name><name><surname>Lidereau</surname><given-names>R</given-names></name></person-group><article-title>Definition of regions of the human genome affected by loss of heterozygosity in primary human breast tumors</article-title><source>J Cell Biochem Suppl</source><year>1993</year><volume>17G</volume><fpage>167</fpage><lpage>172</lpage><pub-id pub-id-type="pmid">8007695</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cropp</surname><given-names>CS</given-names></name><name><surname>Lidereau</surname><given-names>R</given-names></name><name><surname>Leone</surname><given-names>A</given-names></name><name><surname>Liscia</surname><given-names>D</given-names></name><name><surname>Cappa</surname><given-names>AP</given-names></name><name><surname>Campbell</surname><given-names>G</given-names></name><name><surname>Barker</surname><given-names>E</given-names></name><name><surname>Le Doussal</surname><given-names>V</given-names></name><name><surname>Steeg</surname><given-names>PS</given-names></name><name><surname>Callahan</surname><given-names>R</given-names></name></person-group><article-title>NME1 protein expression and loss of heterozygosity mutations in primary human breast tumors</article-title><source>J Natl Cancer Inst</source><year>1994</year><volume>86</volume><fpage>1167</fpage><lpage>1169</lpage><pub-id pub-id-type="pmid">8028038</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bafico</surname><given-names>A</given-names></name><name><surname>Varesco</surname><given-names>L</given-names></name><name><surname>De Benedetti</surname><given-names>L</given-names></name><name><surname>Caligo</surname><given-names>MA</given-names></name><name><surname>Gismondi</surname><given-names>V</given-names></name><name><surname>Sciallero</surname><given-names>S</given-names></name><name><surname>Aste</surname><given-names>H</given-names></name><name><surname>Ferrara</surname><given-names>GB</given-names></name><name><surname>Bevilacqua</surname><given-names>G</given-names></name></person-group><article-title>Genomic PCR-SSCP analysis of the metastasis associated NM23-H1 (NME1) gene: a study on colorectal cancer</article-title><source>Anticancer Res</source><year>1993</year><volume>13</volume><fpage>2149</fpage><lpage>2154</lpage><pub-id pub-id-type="pmid">8297127</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Fig. 1</label><caption><p>The nm23-H1 protein expression by LSAB method. (A) (-), &#x0003c;5% positive cells; (B) (1+), 5-50% positive cells; (C) (2+), &#x0003e;50% positive cells.</p></caption><graphic xlink:href="jkms-21-645-g001"/></fig><fig id="F2" position="float"><label>Fig. 2</label><caption><p>The survival curve according to nm23-H1 protein expression (<italic>p</italic>=0.0039). -, less than 5% of tumor cells were positive; 1+, 5-50% of tumor cells were positive; 2+, more than 50% of the tumor cells were positive.</p></caption><graphic xlink:href="jkms-21-645-g002"/></fig><fig id="F3" position="float"><label>Fig. 3</label><caption><p>The survival curve of nm23-H1 protein expression in B cell lymphoma (A) and T cell lymphoma (B) (<italic>p</italic>=0.0013). -, less than 5% of tumor cells were positive; 1+, 5-50% of tumor cells were positive; 2+, more than 50% of the tumor cells were positive.</p></caption><graphic xlink:href="jkms-21-645-g003"/></fig><fig id="F4" position="float"><label>Fig. 4</label><caption><p>The survival curve of nm23-H1 protein expression according to the same Ann Arbor clinical stage (A, Stage III and IV, <italic>p</italic>=0.0042) and the same International Prognostic Index (B, IPI 2 and 3, <italic>p</italic>=0.0483).</p><p>-, less than 5% of tumor cells were positive; 1+, 5-50% of tumor cells were positive; 2+, more than 50% of the tumor cells were positive.</p></caption><graphic xlink:href="jkms-21-645-g004"/></fig><fig id="F5" position="float"><label>Fig. 5</label><caption><p><italic>nm23-H1</italic> mutation by sequencing. (A) All of four cases with exon 1 mutation show the point mutation at the same site (*, C &#x02190; G). (B) Three of four cases with exon 2 mutation reveal the insertional mutation at the same site (*).</p></caption><graphic xlink:href="jkms-21-645-g005"/></fig><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>The nm23-H1 protein expression according to the histologic types</p></caption><graphic xlink:href="jkms-21-645-i001"/><table-wrap-foot><fn><p>DLBCL, Diffuse large B cell lymphoma; MZL, Marginal zone B cell lymphoma; MCL, Mantle cell lymphoma; TCLNOS, Peripheral T cell lymphoma, not otherwise specified; NK/T, NK/T cell lymphoma. -, less than 5% of tumor cells were positive; 1+, 5-50% of tumor cells were positive; 2+, more than 50% of the tumor cells were positive. <italic>p</italic>=0.229.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>The nm23-H1 protein expression according to age, sex and the nodal or extranodal sites</p></caption><graphic xlink:href="jkms-21-645-i002"/><table-wrap-foot><fn><p>-, less than 5% of tumor cells were positive; 1+, 5-50% of tumor cells were positive; 2+, more than 50% of the tumor cells were positive.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>The nm23-H1 protein expression according to the Ann Arbor stage (Stage) and the International Prognostic Index (IPI)</p></caption><graphic xlink:href="jkms-21-645-i003"/><table-wrap-foot><fn><p><sup>*</sup>Value in bold type is statically significant.</p><p>-, less than 5% of tumor cells were positive; 1+, 5-50% of tumor cells were positive; 2+, more than 50% of the tumor cells were positive.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T4" position="float"><label>Table 4</label><caption><p>Univariate analysis of factors influencing overall survival</p></caption><graphic xlink:href="jkms-21-645-i004"/><table-wrap-foot><fn><p><sup>*</sup>Values in bold types are statistically significant.</p><p>Stage, Ann Arbor stage; IPI, International Prognostic Index (IPI); -, less than 5% of tumor cells were positive; 1+, 5-50% of tumor cells were positive; 2+, more than 50% of the tumor cells were positive.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T5" position="float"><label>Table 5</label><caption><p><italic>nm23-H1</italic> mutation according to the histologic types</p></caption><graphic xlink:href="jkms-21-645-i005"/><table-wrap-foot><fn><p><italic>p</italic>=0.127.</p></fn></table-wrap-foot></table-wrap></floats-group></article>